Skip to main navigation

- Landos - Corp Menu

About Us
- Our Company
- Contact Us
Product Candidates
Science
Investors/Media
Careers
- Why Landos?
- Open Positions

Press Releases

Year

4/13/21

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

4/6/21

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

3/4/21

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

2/23/21

Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

2/3/21

Landos Biopharma Announces Pricing of Initial Public Offering

1/4/21

Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis

Investors/Media

Investors/Media

Investor Relations

Investor/Media Home
Press Releases
Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs

- Landos - Investor Tools

Print Page
RSS Feeds
Email Alerts

Contact

Investor Contact

Thomas Hoffmann
Solebury Trout
646-378-2931
thoffmann@troutgroup.com

Media Contact

Hannah Gendel
Solebury Trout
646-378-2943
hgendel@soleburytrout.com

Landos Biopharma, Inc.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060

info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

Site Map
Terms of Use
Privacy Policy

©2021 Landos Biopharma All Rights Reserved.